Maplirpacept is a protein designed to activate phagocytosis (process by which certain living cells called phagocytes ingest or engulf other cells or particles) and may prevent the formation or growth of tumors (called antitumor activity).

SparkCures ID 344
Developed By Trillium Therapeutics, Inc, a Pfizer company
Generic Name Maplirpacept
Additional Names TTI-622
Treatment Classifications
Treatment Targets

Clinical Trials


There are no resources, links or videos to display for this treatment.

SparkCures Verified

SparkCures is working closely with Trillium Therapeutics, Inc, a Pfizer company to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.

Learn more about how we work with industry partners